Alzheimer’s disease is the leading cause of dementia, impacting millions of seniors worldwide. It gradually destroys brain cells, leading to memory loss, confusion, and difficulties with thinking and daily activities. Experts understand that brain changes begin years before symptoms show.
For this reason, scientists have been exploring simple ways to identify individuals at high risk long before noticeable memory issues develop. One promising method is a blood test that detects a protein called phosphorylated tau 217, or p-tau217. Normally, tau proteins are present in the brain, but in Alzheimer’s, they become abnormal and form tangles that harm brain tissue.
Recently, a blood test measuring p-tau217 gained approval from U.S. regulators, sparking hope that it could serve as an accessible tool for detecting Alzheimer’s-related brain changes without expensive scans. A new international study led by researchers at the Mass General Brigham Neuroscience Institute evaluated how well this blood test predicts future memory decline in cognitively healthy individuals.
Data from six studies across North America, Australia, and Japan was pooled, including 2,684 older adults with normal mental function. All participants provided blood samples for p-tau217 testing and underwent PET scans of the brain at the start. They also completed annual assessments of memory and thinking. Some had been followed since 2004, with the latest evaluations extending into 2025.
During the study, 478 participants developed cognitive impairment. Results showed that those with very high p-tau217 levels had a significantly increased risk of future memory and thinking problems. Their chances reached 38% within five years and climbed to 78% over ten years, though the long-term estimate should be interpreted cautiously due to fewer participants at that stage.
Crucially, the blood test predicted future risk even after accounting for other known factors like amyloid plaques seen on PET scans and genetic risk factors such as the APOE4 gene variant. This suggests p-tau217 might provide unique insights beyond existing diagnostic tools.
Despite these promising findings, researchers emphasize that the blood test isn’t currently recommended for healthy individuals without symptoms. Limited treatment options mean that simply knowing your risk doesn’t yet change medical management. Dr. Reisa Sperling, the study’s senior author, advised that current recommendations remain unchanged: stay physically active, maintain a healthy diet, get quality sleep, and prioritize overall wellness.
This may change in the future if prevention trials succeed with new treatments that can delay or prevent Alzheimer’s. Blood tests like p-tau217 could then help identify who might benefit most from early intervention and closer monitoring.
The study has some limitations. Most participants were drawn from research cohorts rather than the general population, which might limit how broadly the results apply. Longer follow-up is needed to better understand lifetime risk, beyond the five- and ten-year estimates.
Overall, this research marks a big step toward tailored Alzheimer’s risk prediction. It highlights the potential of a simple blood test to help doctors estimate an individual’s future risk—similar to how cholesterol tests predict heart disease risk. More research will be necessary before such testing becomes routine for healthy adults.
If you’re interested in Alzheimer’s prevention, consider reading about how dietary antioxidants may protect against the disease, or how specific eating habits might influence risk. Recent studies also suggest that oral cannabis extracts could help reduce symptoms, and vitamin E might play a role in preventing Parkinson’s disease.
Source: Mass General Brigham.